| Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC) E Francini, KP Gray, W Xie, GK Shaw, L Valença, B Bernard, L Albiges, ... The Prostate 78 (12), 889-895, 2018 | 132 | 2018 |
| Tumor fraction in cell-free DNA as a biomarker in prostate cancer AD Choudhury, L Werner, E Francini, XX Wei, G Ha, SS Freeman, ... JCI insight 3 (21), 2018 | 112 | 2018 |
| Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine+ FOLFOX followed by subcutaneous granulocyte macrophage colony … P Correale, P Tagliaferri, A Fioravanti, MT Del Vecchio, C Remondo, ... Clinical Cancer Research 14 (13), 4192-4199, 2008 | 97 | 2008 |
| Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids G Francini, R Petrioli, A Montagnani, A Cadirni, S Campagna, E Francini, ... British journal of cancer 95 (2), 153-158, 2006 | 88 | 2006 |
| Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials RB Moreira, M Debiasi, E Francini, PV Nuzzo, G De Velasco, FC Maluf, ... Oncotarget 8 (48), 84572, 2017 | 84 | 2017 |
| Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin R Petrioli, A Pascucci, E Francini, S Marsili, A Sciandivasci, R Tassi, ... Cancer chemotherapy and pharmacology 61, 105-111, 2008 | 79 | 2008 |
| The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer R Petrioli, AI Fiaschi, E Francini, A Pascucci, G Francini Cancer treatment reviews 34 (8), 710-718, 2008 | 76 | 2008 |
| Sex and adverse events of adjuvant chemotherapy in colon cancer: an analysis of 34 640 patients in the ACCENT database AD Wagner, A Grothey, T Andre, JG Dixon, N Wolmark, DG Haller, ... JNCI: Journal of the National Cancer Institute 113 (4), 400-407, 2021 | 62 | 2021 |
| Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry E Francini, KP Gray, GK Shaw, CP Evan, AA Hamid, CE Perry, PW Kantoff, ... Prostate cancer and prostatic diseases 22 (3), 420-427, 2019 | 54 | 2019 |
| CEA and CA19. 9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab R Petrioli, A Licchetta, G Roviello, A Pascucci, E Francini, G Bargagli, ... Cancer investigation 30 (1), 65-71, 2012 | 47 | 2012 |
| FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer R Petrioli, L Paolelli, S Marsili, S Civitelli, E Francini, T Cioppa, F Roviello, ... Oncology 70 (5), 345-350, 2007 | 41 | 2007 |
| Epirubicin-based compared with docetaxel-based chemotherapy for advanced gastric carcinoma: a systematic review and meta-analysis R Petrioli, G Roviello, L Zanotti, F Roviello, K Polom, A Bottini, L Marano, ... Critical Reviews in Oncology/Hematology 102, 82-88, 2016 | 40 | 2016 |
| Docetaxel activity in the era of life-prolonging hormonal therapies for metastatic castration-resistant prostate cancer E Francini, CJ Sweeney European urology 70 (3), 410-412, 2016 | 38 | 2016 |
| No clear evidence of a clinical benefit of a sequential therapy regimen with abiraterone acetate and enzalutamide E Francini, R Petrioli, G Roviello Expert review of anticancer therapy 14 (10), 1135-1140, 2014 | 37 | 2014 |
| Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab F Francini, A Pascucci, E Francini, ST Miano, G Bargagli, G Ruggiero, ... The Journal of the American Dental Association 142 (5), 506-513, 2011 | 37 | 2011 |
| Oral metronomic chemo-hormonal-therapy of metastatic breast cancer with cyclophosphamide and megestrol acetate A Licchetta, P Correale, C Migali, C Remondo, E Francini, A Pascucci, ... Journal of Chemotherapy 22 (3), 201-204, 2010 | 37 | 2010 |
| Weekly high‐dose calcitriol and docetaxel in patients with metastatic hormone‐refractory prostate cancer previously exposed to docetaxel R Petrioli, A Pascucci, E Francini, S Marsili, A Sciandivasci, G De Rubertis, ... BJU international 100 (4), 775-779, 2007 | 37 | 2007 |
| Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study R Petrioli, G Roviello, AI Fiaschi, L Laera, D Marrelli, F Roviello, ... Cancer chemotherapy and pharmacology 75, 683-690, 2015 | 35 | 2015 |
| Weekly docetaxel and epirubicin in treatment of advanced hormone-refractory prostate cancer R Petrioli, L Paolelli, E Francini, A Manganelli, F Salvestrini, G Francini Urology 69 (1), 142-146, 2007 | 35 | 2007 |
| PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer … E Francini, R Petrioli, G Rossi, L Laera, G Roviello Tumor Biology 35, 10601-10607, 2014 | 33 | 2014 |
